Sequent Scientific Peer Comparison

NSE: SEQUENT | BSE: 512529

₹267.40

₹7.90 (3.04%)

As on 28-Aug-2026IST

Market cap

₹11,662 Cr

Revenue (TTM)

₹3,149 Cr

P/E Ratio

68.1

P/B Ratio

4.1

Div. Yield

0 %

Edit

	Sequent Scientific	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Market cap (₹ Cr)	11,662	1,974	1,731	35,419	32,309
Revenue (₹ Cr)	3,149	326	536	9,683	3,564
Net Profit (₹ Cr)	213.79	129.56	57.20	1,018.97	414.00
Net Margin (%)	6.70	38.70	10.35	10.47	11.23
RoE (%)	10.42	14.64	18.17	21.30	8.38
Price to Earnings	68.13	14.49	30.26	35.02	79.00
Price-To-Book	4.15	4.34	4.98	6.76	6.42

Income Statement (₹ Cr)

	Sequent Scientific	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Operating Revenue	3,420.31	332.60	500.95	7,896.00	3,373.00
Total Income	3,463.86	347.01	515.68	7,968.78	3,510.00
Total Expenditure	2,767.78	250.66	427.60	6,427.14	2,747.00
EBITDA	652.53	81.94	73.35	1,468.85	626.00
Depreciation	233.64	18.88	19.58	384.13	227.00
EBIT	418.89	63.06	53.77	1,084.73	399.00
Interest	69.21	10.93	5.13	175.78	213.00
Other Income	43.55	14.41	14.73	72.79	137.00
Exceptional Items	-44.21	2.94	--	-10.38	-85.00
Profit before Tax	349.03	75.84	63.37	971.35	238.00
Provision for Tax	124.37	18.35	15.24	263.88	39.00
Profit after Tax	224.65	57.48	48.13	707.47	199.00

	Sequent Scientific	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Shareholder's Funds	2,911.06	360.24	329.24	4,446.19	4,940.00
Minority Interest	203.67	7.55	--	195.37	341.00
Non-Current Liabilities	484.39	157.67	68.63	811.91	1,235.00
Current Liabilities	945.90	152.48	162.59	2,668.27	1,622.00
Total Liabilities	4,595.61	677.94	560.46	8,121.73	8,578.00

	Sequent Scientific	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Non-Current Assets	2,290.47	469.38	271.49	3,565.87	5,441.00
Current Assets	2,254.55	208.56	288.97	4,555.86	2,606.00
Total Assets	4,595.61	677.94	560.46	8,121.73	8,578.00
Total Debt*	435.81	188.26	122.50	730.70	2,125.00
Net Current Assets	1,308.65	56.08	126.38	1,887.59	984.00
Contingent Liabilities	26.69	--	0.80	393.94	768.26

	Sequent Scientific	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Cash From Operating Activities	322.91	64.14	43.32	851.71	390.00
Cash Flow from Investing Activities	-84.12	-2.87	-70.59	-94.00	-241.00
Cash from Financing Activities	-123.33	-48.79	29.55	-813.96	-54.00
Net Cash Inflow / Outflow	115.46	12.48	2.27	-56.25	95.00

	Sequent Scientific	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
ROCE (%)	13.10	16.21	16.88	22.49	6.79
ROE (%)	9.06	17.05	15.74	19.19	4.29
ROA (%)	5.25	8.64	9.60	8.94	2.53
EBIT Margin (%)	20.35	28.97	17.58	19.52	22.62
Net Margin (%)	6.49	16.57	9.33	8.88	5.67
Cash Profit Margin (%)	13.40	22.95	13.52	13.61	10.98

	Sequent Scientific	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Revenue Growth (%)	13.75	6.91	36.03	18.59	11.99
EBIT Growth (%)	65.80	48.27	102.84	19.81	67.69
Net Profit Growth (%)	1,324.82	99.42	127.83	34.10	449.12
EPS Growth (%)	337.51	102.41	127.83	30.75	553.20
Book Value Growth (%)	20.14	14.63	16.57	50.94	13.47

	Sequent Scientific	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Price / Earnings	45.14	19.31	26.59	29.84	89.54
Price / Book Value	2.96	2.98	3.89	4.58	3.87
Dividend Yield (%)	0.00	0.87	0.08	0.28	0.00
EV/EBITDA	11.74	13.04	15.86	13.55	27.45
Market Cap (₹ Cr)	8,003.17	1,074.13	1,279.54	20,327.45	19,071.62

	Sequent Scientific	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Debt to Equity	0.16	0.52	0.37	0.16	0.43
Short term debt to equity ratio	0.04	0.07	0.16	0.11	0.09
Current Ratio	2.38	1.37	1.78	1.71	1.61
Quick Ratio	1.53	0.89	1.35	0.98	1.06
Interest Coverage	6.04	7.94	13.36	6.53	2.12

	Sequent Scientific	Hester Biosciences	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Debtors to sales (%)	30.56	28.67	26.13	25.36	17.43
Asset Turnover	0.80	0.50	1.00	1.01	0.49
Receivable days	98.80	92.43	77.86	87.83	58.75
Inventory Days	79.26	78.37	44.28	78.64	75.82
Payable days	126.90	120.46	88.92	174.97	186.21
Cash Conversion Cycle	51.16	50.33	33.22	-8.50	-51.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.